Page last updated: 2024-11-05

troclosene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID16726
CHEMBL ID2111065
SCHEMBL ID166386
SCHEMBL ID12145618
MeSH IDM0058312

Synonyms (56)

Synonym
dichlorocyanuric acid
troclosene
s-triazine-2,4,6(1h,3h,5h)-trione, 1,3-dichloro-
troclosene [inn]
dichloro-1,3,5-triazinetrione
orced
ai3-25257
1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3-dichloro-
cdb 60
fi clor 71
un2465
caswell no. 327
dichloro-s-triazinetrione
dichloro-s-triazine-2,4,6(1h,3h,5h)-trione
acl 70
dichloroisocyanurate
hilite 60
einecs 220-487-5
hsdb 5897
epa pesticide chemical code 081401
kyselina dichlorisokyanurova [czech]
isocyanuric dichloride
dichloro-s-triazine-2,4,6-trione
1,3-dichloro-s-triazine-2,4,6-trione
isocyanuric acid, dichloro-
ccris 4787
1,3-dichloro-1,3,5-triazinane-2,4,6-trione
1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3-dichloro-, sodium salt
2782-57-2
dichloroisocyanuric acid
D08650
troclosene (dcf)
taharsept (tn)
unii-phr838y52l
kyselina dichlorisokyanurova
phr838y52l ,
NCGC00255350-01
cas-2782-57-2
dtxcid104993
dtxsid8024993 ,
tox21_302395
AKOS006227853
sodium troclosene
SCHEMBL166386
troclosene [hsdb]
1,3-dichloro-s-triazine-2,4,6(1h,3h,5h)trione
troclosene [who-dd]
troclosene [mart.]
SCHEMBL12145618
CHEMBL2111065
W-109823
sr-01000944881
SR-01000944881-1
trion
Q425286
BS-43824

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" There were no adverse clinical events."( Safety of troclosene sodium solution in decontamination of wounds: A prospective clinical and laboratory study.
Bryzgalin, L; Franco, E; Har-Shai, Y; Hassan, S; Lavi, I; Metanes, I; O'Boyle, CP; Sadeh, O; Segal, M,
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency54.48270.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency76.95880.000221.22318,912.5098AID743042
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency46.22710.057821.109761.2679AID1159528
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (108)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (15.74)18.7374
1990's19 (17.59)18.2507
2000's26 (24.07)29.6817
2010's37 (34.26)24.3611
2020's9 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.24 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index79.35 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (50.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.69%)5.53%
Reviews4 (3.39%)6.00%
Case Studies5 (4.24%)4.05%
Observational0 (0.00%)0.25%
Other107 (90.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Health Impact of Treating and Safely Storing Shallow Tubewell Drinking Water [NCT01350063]1,800 participants (Actual)Interventional2011-02-28Completed
Health Impact Study of a Water Treatment Tablet, Aquatabs, in Tamale, Ghana [NCT00252928]240 participants (Actual)Interventional2006-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]